journal
MENU ▼
Read by QxMD icon Read
search

Annals of Hematology

journal
https://www.readbyqxmd.com/read/29164292/incidence-and-impact-of-atrial-arrhythmias-on-thrombotic-events-in-mpns
#1
Kristell Mahé, Aurélien Delluc, Aurélie Chauveau, Philippe Castellant, Dominique Mottier, Florence Dalbies, Christian Berthou, Gaëlle Guillerm, Eric Lippert, Jean-Christophe Ianotto
Atrial arrhythmias (AA) induce a high rate of thromboses and require vitamin K antagonists (VKA) or direct anticoagulants (DOAC) prescriptions. Essential thrombocythemia (ET) and polycythemia vera (PV) are also pro-thrombotic diseases. The prevention of thromboses is based on the association of cytoreductive drug and low-dose aspirin (LDA). We studied the incidence and complications of AA among patients with ET or PV. We identified 96/713 patients (13.5%) carrying AA. These patients were older (median 72.1 vs...
November 21, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29159499/redistribution-of-cell-cycle-by-arsenic-trioxide-is-associated-with-demethylation-and-expression-changes-of-cell-cycle-related-genes-in-acute-promyelocytic-leukemia-cell-line-nb4
#2
Saeed Hassani, Ali Khaleghian, Shahin Ahmadian, Shaban Alizadeh, Kamran Alimoghaddam, Ardeshir Ghavamzadeh, Seyed H Ghaffari
PML-RARα perturbs the normal epigenetic setting, which is essential to oncogenic transformation in acute promyelocytic leukemia (APL). Transcription induction and recruitment of DNA methyltransferases (DNMTs) by PML-RARα and subsequent hypermethylation are components of this perturbation. Arsenic trioxide (ATO), an important drug in APL therapy, concurrent with degradation of PML-RARα induces cell cycle change and apoptosis. How ATO causes cell cycle alteration has remained largely unexplained. Here, we investigated DNA methylation patterns of cell cycle regulatory genes promoters, the effects of ATO on the methylated genes and cell cycle distribution in an APL cell line, NB4...
November 20, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29159498/pooled-analysis-of-the-reports-of-carfilzomib-ixazomib-combinations-for-relapsed-refractory-multiple-myeloma
#3
Wenjun Xu, Xuedong Sun, Baohong Wang, Hui Guo
We sought to evaluate the activity and safety of carfilzomib-/ixazomib-containing combinations for patients with relapsed/refractory multiple myeloma (RRMM). We searched published reports including carfilzomib-/ixazomib-containing combinations for RRMM. Finally, we identified 11 prospective studies covering 2845 relapsed/refractory patients. Carfilzomib- and ixazomib-containing combinations respectively resulted in an impressive overall response rate (ORR 77 vs. 64%, P = 0.14), very good partial response or better (≥ VGPR 48 vs...
November 20, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29151134/kit-d816v-chronic-myelomonocytic-leukemia-progressing-to-kit-d816v-associated-to-mast-cell-leukemia-responding-to-allogeneic-hematopoietic-cell-transplantation
#4
LETTER
Concepción Prats-Martín, Patricia Jiménez-Guerrero, Rosario M Morales-Camacho, Teresa Caballero-Velázquez, M Teresa Vargas, Olga Pérez, Isabel Montero, José Falantes, Sergio Burillo-Sanz, Estrella Carrillo, Juan J Borrero, Ricardo Bernal, J A Pérez-Simón
No abstract text is available yet for this article.
November 18, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29151133/treatment-of-relapsed-aml-and-mds-after-allogeneic-stem-cell-transplantation-with-decitabine-and-dli-a-retrospective-multicenter-analysis-on-behalf-of-the-german-cooperative-transplant-study-group
#5
Thomas Schroeder, Christina Rautenberg, William Krüger, Uwe Platzbecker, Gesine Bug, Juliane Steinmann, Stefan Klein, Olaf Hopfer, Kathrin Nachtkamp, Mustafa Kondakci, Stefanie Geyh, Rainer Haas, Ulrich Germing, Martin Bornhäuser, Guido Kobbe
In contrast to the evidence regarding azacitidine (Aza), there is limited knowledge about the combination of decitabine (DAC) and donor lymphocyte infusions as salvage therapy for relapse after allogeneic stem cell transplantation (allo-SCT) so far. We retrospectively analyzed data of 36 patients with hematological (n = 35) or molecular relapse (n = 1) of acute myeloid leukemia (AML, n = 29) or myelodysplastic syndrome (MDS, n = 7) collected from 6 German transplant centers. Patients were treated with a median of 2 cycles DAC (range, 1 to 11)...
November 18, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29150812/factors-influencing-platelet-transfusion-refractoriness-in-patients-undergoing-allogeneic-hematopoietic-stem-cell-transplantation
#6
Pilar Solves, Jaime Sanz, Carmen Freiria, Marta Santiago, Ana Villalba, Inés Gómez, Pau Montesinos, Juan Montoro, Jose Luis Piñana, José Ignacio Lorenzo, Nieves Puig, Guillermo F Sanz, Miguel Ángel Sanz, Nelly Carpio
Hematopoietic stem cell transplantation has been considered a risk factor for development of platelet transfusion refractoriness. The objective of this study was to assess the platelet transfusion refractoriness rate in patients undergoing allogeneic hematopoietic stem cell transplantation from different sources. We retrospectively reviewed the charts and transfusion records of patients who underwent allogeneic stem cell transplantation at our institution between 2013 and 2015. The evaluation of post-transfusion platelet count was assessed for each transfusion given, from day of progenitor infusion to day 30 after transplantation...
November 17, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29150811/alk-expression-plays-different-roles-in-anaplastic-large-cell-lymphomas-and-outcome-of-crizotinib-use-in-relapsed-refractory-alk-patients-in-a-chinese-population
#7
Ling Huang, Fen Zhang, Jialong Zeng, Hanguo Guo, Sichu Liu, Xiaojuan Wei, Feili Chen, Xinmiao Jiang, Zhanli Liang, Yanhui Liu, Wenyu Li
The prognostic value of anaplastic lymphoma kinase (ALK) expression in patients with anaplastic large-cell lymphoma (ALCL) remains controversial. Data on the clinical features of ALCL in a Chinese population are limited. We retrospectively reviewed 1293 patients with pathologically diagnosed lymphoma at Guangdong General Hospital from June 2007 through August 2016. We evaluated the incidence of ALCL, clinical characteristics, survival status, and outcome of crizotinib use in four relapsed/refractory ALK-positive patients...
November 17, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29150810/liver-fibrosis-alleviation-after-co-transplantation-of-hematopoietic-stem-cells-with-mesenchymal-stem-cells-in-patients-with-thalassemia-major
#8
Ardeshir Ghavamzadeh, Masoud Sotoudeh, Amir Pejman Hashemi Taheri, Kamran Alimoghaddam, Hossein Pashaiefar, Mahdi Jalili, Farhad Shahi, Mohammad Jahani, Marjan Yaghmaie
The aims of this study are to determine the replacement rate of damaged hepatocytes by donor-derived cells in sex-mismatched recipient patients with thalassemia major and to determine whether co-transplantation of mesenchymal stem cells and hematopoietic stem cells (HSCs) can alleviate liver fibrosis. Ten sex-mismatched donor-recipient pairs who received co-transplantation of HSCs with mesenchymal stem cells were included in our study. Liver biopsy was performed before transplantation. Two other liver biopsies were performed between 2 and 5 years after transplantation...
November 17, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29147848/simultaneous-point-of-care-detection-of-anemia-and-sickle-cell-disease-in-tanzania-the-rapid-study
#9
Luke R Smart, Emmanuela E Ambrose, Kevin C Raphael, Adolfine Hokororo, Erasmus Kamugisha, Erika A Tyburski, Wilbur A Lam, Russell E Ware, Patrick T McGann
Both anemia and sickle cell disease (SCD) are highly prevalent across sub-Saharan Africa, and limited resources exist to diagnose these conditions quickly and accurately. The development of simple, inexpensive, and accurate point-of-care (POC) assays represents an important advance for global hematology, one that could facilitate timely and life-saving medical interventions. In this prospective study, Robust Assays for Point-of-care Identification of Disease (RAPID), we simultaneously evaluated a POC immunoassay (Sickle SCAN™) to diagnose SCD and a first-generation POC color-based assay to detect anemia...
November 16, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29147847/r-hyper-cvad-versus-r-chop-cytarabine-with-high-dose-therapy-and-autologous-haematopoietic-stem-cell-support-in-fit-patients-with-mantle-cell-lymphoma-20%C3%A2-years-of-single-center-experience
#10
Fabienne Widmer, Stefan Balabanov, Davide Soldini, Panagiotis Samaras, Bernhard Gerber, Markus G Manz, Jeroen S Goede
Standard of care for untreated mantle cell lymphoma (MCL) is still debated. At the University Hospital Zurich, advanced MCL in physically fit patients is treated either with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone induction followed by consolidating high-dose chemotherapy and autologous stem cell support (R-CHOP/HD-ASCT), or with rituximab plus fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with high-dose methotrexate-cytarabine (R-hyper-CVAD/MTX-AraC) without consolidating HD-ASCT upon physicians' and patients' choice...
November 16, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29143865/paraneoplastic-pemphigus-without-detectable-anti-plakin-antibodies-in-a-patient-with-non-hodgkin-lymphoma
#11
LETTER
E Moreno-Artero, E Querol-Cisneros, N Rodríguez-Garijo, A Tomás-Velázquez, M A Idoate, N Ishii, T Hashimoto, Agustín España
No abstract text is available yet for this article.
November 16, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29143068/patient-characteristics-and-outcomes-in-adolescents-and-young-adults-with-classical-philadelphia-chromosome-negative-myeloproliferative-neoplasms
#12
Prajwal Boddu, Lucia Masarova, Srdan Verstovsek, Paolo Strati, Hagop Kantarjian, Jorge Cortes, Zeev Estrov, Sherry Pierce, Naveen Pemmaraju
Little is known about the outcomes of Philadelphia-negative myeloproliferative neoplasms (MPNs) in adolescents and young adults (AYA). We reviewed all patients with essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF) treated at our institution from 1988 to 2016 who were aged 16 to 39 years (AYA) and described their outcomes in comparison to older MPN population. Of 2206 patients, 185 (8.3%) were identified as AYA: 105 (57%) ET, 43 (23%) PV, and 37 (20%) MF. The median age was 33 years [range, 16-39], and median follow-up time 3 years [range, 0...
November 15, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29138886/clinical-predictors-of-stenotrophomonas-maltophilia-bacteremia-in-adult-patients-with-hematologic-malignancy
#13
Si-Ho Kim, Sun Young Cho, Cheol-In Kang, Hyeri Seok, Kyungmin Huh, Young Eun Ha, Doo Ryeon Chung, Nam Yong Lee, Kyong Ran Peck, Jae-Hoon Song
Stenotrophomonas maltophilia (SM) has emerged as an important nosocomial pathogen with high morbidity and mortality. Because of its unique antimicrobial susceptibility pattern, appropriate antimicrobial therapy for SM bacteremia is still challenging, especially in immunocompromised patients. The present study was performed to assess clinical predictors of SM bacteremia in adult patients with hematologic malignancy. From 2006 through 2016, a case-control study was performed at a tertiary-care hospital. Case patients were defined as SM bacteremia in patients with hematologic malignancy...
November 14, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29138885/delayed-recovery-of-serum-immunoglobulin-g-is-a-poor-prognostic-marker-in-patients-with-follicular-lymphoma-treated-with-rituximab-maintenance
#14
Yoshiharu Kusano, Masahiro Yokoyama, Norihito Inoue, Hirofumi Yamauchi, Anna Takahashi, Naoko Tsuyama, Yuko Mishima, Noriko Nishimura, Kengo Takeuchi, Yasuhito Terui, Kiyohiko Hatake
Clinical trials involving various treatment schedules for rituximab maintenance have been conducted for patients with follicular lymphoma (FL) and have not confirmed their impact on serum immunoglobulin (sIg) levels until the completion of maintenance. However, the long-term use of rituximab is a concern because of circulating plasma cell-depletion risk, suggesting that the mechanism of change in sIg levels after RM has not been determined. Additionally, the relationship between host humoral immunity and the prognosis of patients with B cell malignancies has not been determined...
November 14, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29134269/sclerosing-mesenteritis-as-a-presentation-of-myelodysplastic-syndrome-mds-with-improvement-following-treatment-targeted-at-mds
#15
LETTER
Radowan Elnair, Prince Sethi, Tarek Hassouna, Ahmed Galal
No abstract text is available yet for this article.
November 13, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29130135/a-patient-with-acquired-factor-x-deficiency-and-metastatic-transitional-cell-carcinoma-of-the-bladder-is-there-a-link-between-metastasis-and-factor-deficiency-in-solid-tumors
#16
LETTER
T Cammaert, K Decaestecker, N Sundahl, S Rottey, K M J Devreese
No abstract text is available yet for this article.
November 13, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29130134/is-it-possible-to-improve-prognostic-value-of-nccn-ipi-in-patients-with-diffuse-large-b-cell-lymphoma-the-prognostic-significance-of-comorbidities
#17
Darko Antic, Jelena Jelicic, Goran Trajkovic, Milena Todorovic Balint, Jelena Bila, Olivera Markovic, Ivan Petkovic, Vesna Nikolic, Bosko Andjelic, Vladislava Djurasinovic, Aleksandra Sretenovic, Mihailo Smiljanic, Vojin Vukovic, Biljana Mihaljevic
The prognostic value of the International Prognostic Index (IPI) has been re-evaluated in the rituximab-treated diffuse large B cell lymphoma (DLBCL) patients. Accordingly, National Comprehensive Cancer Network-IPI (NCCN-IPI) has been introduced to estimate prognosis of DLBCL patients. However, comorbidities that frequently affect elderly DLBCL patients were not analyzed. The aim of this study was to evaluate the prognostic significance of comorbidities using Charlson Comorbidity Index (CCI) in 962 DLBCL patients...
November 12, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29130133/infusion-of-leukocytes-from-hla-haplo-identical-familial-donors-as-an-adjuvant-in-the-hlh-2004-protocol-to-treat-the-virus-associated-adult-hemophagocytic-lymphohistiocytosis-a-retrospective-study-of-26-patients
#18
Hui Zhang, Zhiming Dai, Nan Yang, Jin Wang, Aili He, Jianli Wang, Yang Zhang, Shan Meng, Baiyan Wang, Rong Sun, Wanggang Zhang
Adult hemophagocytic lymphohistiocytosis (HLH) is a fatal disease with poor survival and a limited role of drug therapies. To help to recognize virus and enhance survival, we infused leukocytes derived from human leukocyte antigen (HLA) haplo-identical familial donors to patients. We retrospectively investigated 26 adult virus-associated hemophagocytic syndrome (VAHS) patients' medical records from 2006-2017. Eleven of the 26 patients accepted relatives' derived leukocytes infusions in addition to drug therapies recommended in the HLH-2004 protocol...
November 12, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29128997/pd-1-pd-l1-immune-checkpoint-blockade-in-malignant-lymphomas
#19
REVIEW
Yi Wang, Ling Wu, Chen Tian, Yizhuo Zhang
Tumor cells can evade immune surveillance through overexpressing the ligands of checkpoint receptors on tumor cells or adjacent cells, leading T cells to anergy or exhaustion. Growing evidence of the interaction between tumor cells and microenvironment promoted the emergence of immune-checkpoint blockade. By targeting programmed cell death-1 (PD-1) pathway, cytotoxic activity of T cell is enhanced significantly and tumor cell lysis is induced subsequently. Currently, various antibodies against PD-1 and programmed death-ligand 1 (PD-L1) are under clinical studies in lymphomas...
November 11, 2017: Annals of Hematology
https://www.readbyqxmd.com/read/29124313/simultaneous-occurrence-of-two-distinct-leukemic-clones-with-pml-rar%C3%AE-and-runx1-runx1t1-in-a-case-of-acute-myeloid-leukemia
#20
LETTER
Haigang Shao, Qian Yang, Ping Zhang, Hengfang Liu, Chunxiao Wu, Jiannong Cen, Huiying Qiu, Suning Chen, Jinlan Pan
No abstract text is available yet for this article.
November 9, 2017: Annals of Hematology
journal
journal
30731
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"